Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.

Clinical studies showed that high doses of recombinant human erythropoietin (rHuEPO) used to correct anaemia in chronic kidney disease (CKD) hyporesponsive patients may lead to deleterious effects. The aim of this study was to analyze the effects of rHuEPO in doses usually used to correct CKD-anaemi...

Full description

Bibliographic Details
Main Author: Ribeiro, Sandra (author)
Other Authors: Garrido, Patrícia (author), Fernandes, João (author), Vala, Helena (author), Rocha-Pereira, Petronila (author), Costa, Elísio (author), Belo, Luís (author), Reis, Flávio (author), Santos-Silva, Alice (author)
Format: article
Language:eng
Published: 2020
Subjects:
anaemia
high rHuEPO doses
hypertension
hyporesponsiveness
inflammation
Online Access:http://hdl.handle.net/10400.19/6229
Country:Portugal
Oai:oai:repositorio.ipv.pt:10400.19/6229

Internet

http://hdl.handle.net/10400.19/6229

Similar Items